BSX - Boston Scientific Corporation
| Previous Close | 43.20 |
| Open | 43.20 |
| Bid | 44.00 x 800 |
| Ask | 44.28 x 3200 |
| Day's Range | 43.14 - 44.31 |
| 52 Week Range | 34.35 - 46.62 |
| Volume | 15,909,751 |
| Avg. Volume | 6,823,669 |
| Market Cap | 61.718B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | 57.51 |
| EPS (TTM) | 0.77 |
| Earnings Date | Feb 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.62 |
- Zacks
Boston Scientific Gets a Boost From New Products, Buyouts
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
- Zacks
3 Medical Product Stocks Set to Beat This Earnings Season
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
- Zacks
Boston Scientific Stock Dips on Dull Preliminary Q4 Results
Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.
- Investor's Business Daily
Medtech CEO Bullish After Preliminary Fourth-Quarter Report Disappoints
Boston Scientific preliminarily announced disappointing fourth-quarter sales on Tuesday, sending BSX stock into a tailspin. The biggest shortfall came from cardiac rhythm management.
- Zacks
HRC or BSX: Which Is the Better Value Stock Right Now?
HRC vs. BSX: Which Stock Is the Better Value Option?
- MarketWatch
Boston Scientific's stock falls after downbeat sales update
Shares of Boston Scientific Corp. dropped 6.3% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below expectations. On a preliminary basis, sales rose 13.4% to $2.90 billion, below the FactSet consensus of $2.93 billion, as MedSurg revenue rose 9.8%, Rhythm and Neuro grew 3.5%, Cardiovascular increased 18.7% and medical devices rose 11.2%. The company said it is still closing its books for the quarter, but estimates it will report adjusted earnings per share within its previously issued guidance range of 42 cents to 45 cents; the FactSet consensus was 44 cents. The stock has run up 19.8% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has rallied 14.0% and the S&P 500 has gained 10.9%.
- PR Newswire
Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019
Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company's guidance range of 13 to 15 percent; approximately 14.1 percent on an operational1 basis, compared to the company's guidance range of 14 to 16 percent; and approximately 7.3 percent on an organic2 basis, compared to the company's guidance range of 8 to 9 percent, all compared to the prior year period.
- PR Newswire
Boston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results
Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:00 a.m. PST / 11:00 a.m. EST. At 8:30 a.m. PST / 11:30 a.m. EST, Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Ian Meredith, MD, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host analyst and audience members.
- Simply Wall St.
I Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- American City Business Journals
Court orders Boston Scientific to complete $275M acquisition
Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation.
- Insider Monkey
Boston Scientific Corporation (BSX) vs. Top 20 Hedge Fund Stocks in 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 44.6% this year and beat the S&P 500 ETFs by […]
- GuruFocus.com
Signature Select Canadian Fund's Top 5 Buys
Fund’s top buy is in gold ETF. It also enters a small stake in Buffett’s conglomerate Continue reading...
- Benzinga
The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...
- Zacks
Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod
Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.
- Zacks
Boston Scientific Hits New 52-Week High: What's Driving it?
Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.
- PR Newswire
Boston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALTâ„¢ Model D
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALTâ„¢ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures. The EXALT Model D Duodenoscope is the first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.
- Kiplinger
The 13 Best Health-Care Stocks to Buy for 2020
One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
- American City Business Journals
South Texas Military Contracting Roundup: more than $46M in contracts awarded
This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.
- Simply Wall St.
Calculating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...
- Zacks
Boston Scientific's Watchman Implant Study Results Encourage
These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.
- American City Business Journals
Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
- GuruFocus.com
Urbem's 'Wonderful Business' Series: Intuitive Surgical
A near-monopoly pioneer in a fast-growing space Continue reading...
- Insider Monkey
Is Boston Scientific Corporation (BSX) A Good Stock To Buy?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]
- Zacks
Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
